These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 32593400)

  • 21. ErbB Receptors and Cancer.
    Wang Z
    Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mechanisms of Resistance to the Third-generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer].
    Ni L; Nie L
    Zhongguo Fei Ai Za Zhi; 2018 Feb; 21(2):110-115. PubMed ID: 29526178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
    Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
    Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective study of the use of circulating markers as predictors for epidermal growth factor receptor-tyrosine kinase inhibitor treatment in pulmonary adenocarcinoma.
    Luo YH; Tseng PC; Lee YC; Perng RP; Whang-Peng J; Chen YM
    Cancer Biomark; 2016; 16(1):19-29. PubMed ID: 26484608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
    Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
    Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
    Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
    J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.
    Urtasun N; Vidal-Pla A; Pérez-Torras S; Mazo A
    BMC Cancer; 2015 Apr; 15():223. PubMed ID: 25886138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
    Naruse I; Ohmori T; Ao Y; Fukumoto H; Kuroki T; Mori M; Saijo N; Nishio K
    Int J Cancer; 2002 Mar; 98(2):310-5. PubMed ID: 11857424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.
    Kim SM; Kwon OJ; Hong YK; Kim JH; Solca F; Ha SJ; Soo RA; Christensen JG; Lee JH; Cho BC
    Mol Cancer Ther; 2012 Oct; 11(10):2254-64. PubMed ID: 22891040
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Third Shot at EGFR: New Opportunities in Cancer Therapy.
    Guardiola S; Varese M; Sánchez-Navarro M; Giralt E
    Trends Pharmacol Sci; 2019 Dec; 40(12):941-955. PubMed ID: 31706618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
    Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
    Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
    Liang Y; Zhang T; Zhang J
    Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
    Li J; Zhang L; Zhu H; Pan W; Zhang N; Li Y; Yang M
    DNA Cell Biol; 2018 Nov; 37(11):903-908. PubMed ID: 30277797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling therapy resistance via the EGFR signaling pathway.
    Plattner C; Hackl H
    FEBS J; 2019 Apr; 286(7):1284-1286. PubMed ID: 30892828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mechanisms of resistance to EGFR targeted therapies.
    Hrustanovic G; Lee BJ; Bivona TG
    Cancer Biol Ther; 2013 Apr; 14(4):304-14. PubMed ID: 23358468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical research and drug review of epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer].
    Zhou M; Chen DM; Xia L; Song YY; Shi YK; Yang ZM
    Zhonghua Zhong Liu Za Zhi; 2019 Dec; 41(12):949-952. PubMed ID: 31874554
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.